Do any peptides help perimenopause sleep problems and night sweats?

The short answer

Evidence tier: 1 — FDA/EMA labels, phase 3 trials and society guidelines for proven options; tiers 4–5 for the peptides.

No peptide has been shown in a controlled trial to fix perimenopausal sleep or night sweats. None of the peptides people try (DSIP, ipamorelin, CJC-1295, epitalon) has been tested in menopausal women for these problems.

The treatments with real evidence are menopausal hormone therapy (MHT), CBT for insomnia, and two newer non-hormonal drugs, fezolinetant and elinzanetant. The two drugs are not peptides. They work by blocking a peptide signal, neurokinin B, in the brain's temperature centre. That signal comes from the same KNDy neurons that produce kisspeptin, which is why kisspeptin research matters here.

DSIP lost a key vote. In July 2026, an FDA advisory committee voted 7–6 against (one abstention) adding emideltide (DSIP) to the US compounding list.

The key points:

• Perimenopausal sleep breaks mainly through night sweats, falling estradiol and falling progesterone.
• MHT improves both hot flushes and sleep quality in randomised trials.
• CBT for insomnia works in women with hot flushes, without drugs.
• Fezolinetant and elinzanetant cut hot flushes and improved self-rated sleep in phase 3 trials.
• Growth hormone peptides have no menopause sleep data, and one study found GHRH made sleep worse in women.

Why does sleep fall apart in perimenopause?

Evidence tier: 3 — large cohort and sleep-laboratory studies.

Sleep problems climb steadily through the transition. In SWAN, a study of over 3,000 midlife women, trouble falling and staying asleep rose as women moved through the menopause transition. More frequent hot flushes, lower estradiol and higher FSH each predicted worse sleep.

Three things drive it:

1. Night sweats. In a sleep-lab study, women with hot flushes had more arousals and awakenings in the first half of the night, and most flushes came just before the waking.
2. Falling progesterone. Progesterone has a calming, sedative effect. In a small crossover trial, oral micronised progesterone reduced time awake during the night in postmenopausal women.
3. Mood and brain-circuit changes. A 2024 review in Menopause describes the typical pattern as frequent night-time waking and more time awake after falling asleep, linked to the same hypothalamic neurons that control temperature.

What works for menopausal sleep problems?

Evidence tier: 1–2 — randomised trials and guidelines from The Menopause Society and NICE.

Menopausal hormone therapy. The 2022 Menopause Society position statement names MHT as the most effective treatment for hot flushes. In the KEEPS trial, both oral and transdermal estrogen with cyclic progesterone improved sleep quality scores compared with placebo in recently menopausal women. For perimenopause, a Canadian trial of nightly progesterone did not significantly reduce hot flushes, but women reported fewer night sweats and better sleep; the trial was underpowered and could not exclude a hot-flush benefit.

CBT for insomnia (CBT-I). In a randomised trial in women with hot flashes, six telephone sessions cut insomnia severity scores by 9.9 points versus 4.7 with menopause education. NICE's November 2024 menopause update lists CBT as an option for hot flushes, night sweats and sleep problems, alongside or instead of HRT.

Non-hormonal drugs. The Menopause Society's 2023 nonhormone statement gives Level I support to CBT, certain antidepressants, gabapentin and fezolinetant. It does not recommend supplements or herbal remedies.

Which option fits depends on age, time since your last period, and personal risks. That is a decision for you and a physician.

How do fezolinetant and elinzanetant relate to kisspeptin?

Evidence tier: 1 — FDA and EMA approvals and phase 3 RCTs; tier 4 for the brain-circuit mechanism.

Deep in the hypothalamus sit KNDy neurons, named for the three peptides they make: kisspeptin, neurokinin B and dynorphin. Estrogen normally holds them in check. After menopause, these neurons enlarge and become overactive, and they project to the brain's heat-loss centre.

The human evidence that this pathway drives hot flushes:

• In a randomised crossover study, an infusion of neurokinin B triggered hot flushes in 8 of 10 healthy women and in none on placebo.
• Blocking its receptor (NK3) with an experimental drug cut weekly hot flushes by 45% in a 2017 phase 2 trial.

That work led to two approved drugs:

Neither is approved for sleep itself. Both are approved for moderate to severe hot flushes. Their labels carry warnings:

• The Veozah label has a boxed warning for liver injury and requires liver blood tests before and during treatment.
• The Lynkuet label warns of daytime sleepiness, liver enzyme rises and pregnancy loss. In trials, 11.9% had nervous-system effects versus 3.5% on placebo.

Where kisspeptin itself fits: kisspeptin is a real peptide in active human research, mainly for fertility and sexual function (see our kisspeptin article). We found no trial testing kisspeptin for hot flushes or sleep. The approved drugs target neurokinin B, the peptide next to kisspeptin in the same neurons, not kisspeptin.

Does DSIP help menopausal insomnia?

Evidence tier: 2–4 — small, conflicting 1980s–90s trials in general insomnia; none in menopausal women.

DSIP (delta sleep-inducing peptide, also called emideltide) has only small, old human trials, all in general insomnia:

• A 14-patient trial reported better sleep and daytime alertness after seven nights of DSIP.
• A placebo-controlled crossover study concluded the sleep improvement was "of little clinical significance".
• A 16-patient double-blind study found weak effects and concluded DSIP is not likely to be of major therapeutic benefit.

Regulatory status (US): in April 2026 FDA removed DSIP from its "Category 2" list after the nomination was withdrawn. That did not make it legal to compound. At the July 23–24, 2026 advisory committee, members voted 7–6 against (one abstention) emideltide for insomnia, narcolepsy and opioid withdrawal. It was the only one of seven peptides rejected, and it is not among the six peptides covered by the October 2026 HHS enforcement-discretion policy. We found no EMA or MHRA authorisation for DSIP as a medicine. Our DSIP evidence review covers the research in depth.

Do ipamorelin, CJC-1295 or MK-677 improve deep sleep?

Evidence tier: 3–4 — small physiology studies; no data in menopausal women.

The claim rests on a real link: deep (slow-wave) sleep and growth hormone release happen together. The jump from that to "GH peptides fix menopausal sleep" is not supported.

• Ipamorelin and CJC-1295: human studies measure GH and IGF-1 levels, such as a CJC-1295 study in healthy adults. We found no published sleep trial for either.
• GHRH in women: a controlled study found that GHRH, the hormone CJC-1295 imitates, reduced REM and deep sleep in young women, unlike the boost seen in men.
• MK-677 (ibutamoren): an oral drug, not a peptide. A 1997 study in 14 adults found more deep sleep in young people and more REM sleep in older people. A two-year trial in older adults found raised blood glucose, reduced insulin sensitivity and more appetite, which matters in midlife when diabetes risk is rising.

None of these is approved by the FDA, EMA or MHRA. More detail is in our guide to GH peptides and sleep architecture.

Can epitalon or melatonin reset sleep in menopause?

Evidence tier: 2 for melatonin (meta-analysis); 4 for epitalon.

Melatonin has been tested directly in menopausal women. A meta-analysis of randomised trials found no improvement in sleep quality, hot flushes or overall menopausal symptoms.

Epitalon is sold on the idea that it restores melatonin rhythms. The basis is small studies using epithalamin, a related pineal extract, which altered night-time melatonin in elderly people. A 2026 review concluded epitalon is biologically active but clinically unproven, with no adequately powered trial. The FDA advisory committee voted 7–4 in favour of epitalon for insomnia in July 2026, against FDA staff advice. FDA has not added it to the compounding list, but in late October 2026 HHS announced an interim enforcement-discretion policy for compounded epitalon injections while rulemaking continues. That is not an approval and says nothing about whether it works. See our epitalon and sleep article.

What is anecdote only?

Evidence tier: 5 — community reports.

Online forums report better sleep with DSIP, ipamorelin/CJC-1295 stacks, MK-677 and epitalon. These reports cannot separate a drug effect from placebo, from natural ups and downs of perimenopause, or from other changes people make at the same time. Grey-market vials also vary in purity and dose. Our sourcing and safety guide explains the risks.

Limitations of the evidence

Evidence tier: — summary of the evidence gaps above.

• No peptide has been tested in menopausal women for sleep or night sweats.
• DSIP evidence is limited to small, conflicting 1980s–90s trials in general insomnia.
• Ipamorelin and CJC-1295 have no published sleep trials; human studies measure GH and IGF-1 only.
• Epitalon's melatonin data come from small studies of a related extract, epithalamin, with no adequately powered trial.
• The fezolinetant sleep data are post hoc and the elinzanetant sleep data a secondary endpoint; neither drug is approved for sleep.

The bottom line

Perimenopausal insomnia is real and treatable, but not with peptides on current evidence. MHT, CBT-I and the neurokinin-blocking drugs fezolinetant and elinzanetant have trial data in menopausal women. Kisspeptin research explains why those drugs work, but kisspeptin itself is not a sleep treatment. DSIP, GH peptides and epitalon rest on small or indirect studies, and none has been tested for menopausal sleep. A physician can help match the proven options to your health history.

Related on this site

• Peptides for perimenopause and menopause
• DSIP and sleep: what the evidence shows
• GH peptides for sleep architecture
• Pinealon, epitalon and REM sleep
• Kisspeptin and female sexual health
• Are peptides legal in 2026?
• Peptides for women in 2026

References

• Kravitz HM et al. Sleep disturbance during the menopausal transition in a multi-ethnic community sample of women. Sleep 2008 — SWAN; sleep problems rise through the transition. PMID 18652093
• Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006 — sleep-lab study; flushes precede early-night awakenings. PMID 16837879
• Schüssler P et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008 — crossover RCT, n=10. PMID 18676087
• Maki PM et al. Sleep disturbance associated with the menopause. Menopause 2024 — review of causes and KNDy circuitry. PMID 38916279
• The North American Menopause Society. The 2022 hormone therapy position statement. Menopause 2022 — MHT most effective for vasomotor symptoms. PMID 35797481
• Cintron D et al. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains (KEEPS). Menopause 2018 — both MHT forms improved sleep quality vs placebo. PMID 28832429
• Prior JC et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes. Sci Rep 2023 — phase 3 RCT, n=189; improved perceived sleep. PMID 37277418
• McCurry SM et al. Telephone-based CBT for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms. JAMA Intern Med 2016 — MsFLASH RCT, n=106. PMID 27213646
• The North American Menopause Society. The 2023 nonhormone therapy position statement. Menopause 2023 — graded non-hormonal options. PMID 37252752
• NICE. Menopause: identification and management (NG23), November 2024 update — CBT for vasomotor and sleep symptoms. Science Media Centre summary
• Rance NE et al. Modulation of body temperature and LH secretion by hypothalamic KNDy neurons. Front Neuroendocrinol 2013 — mechanism review. PMID 23872331
• Jayasena CN et al. Neurokinin B administration induces hot flushes in women. Sci Rep 2015 — randomised crossover, n=10. PMID 25683060
• Prague JK et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes. Lancet 2017 — phase 2 RCT. PMID 28385352
• Lederman S et al. Fezolinetant for moderate-to-severe vasomotor symptoms (SKYLIGHT 1). Lancet 2023 — phase 3 RCT. PMID 36924778
• Cano A et al. Effect of fezolinetant on sleep, health-related quality of life and work productivity. Climacteric 2026 — post hoc SKYLIGHT 1–2 sleep analysis. PMID 42734219
• Pinkerton JV et al. Elinzanetant for vasomotor symptoms: OASIS 1 and 2 randomized clinical trials. JAMA 2024 — phase 3; sleep a secondary endpoint. PMID 39172446
• FDA. Veozah (fezolinetant) prescribing information — boxed warning for hepatotoxicity. DailyMed
• FDA. Lynkuet (elinzanetant) prescribing information — somnolence, liver and pregnancy warnings. DailyMed
• EMA. Lynkuet EPAR — EU authorisation 17 November 2025. EMA
• EMA. Veoza EPAR — EU authorisation 7 December 2023. EMA
• MHRA. MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms. 2025 — UK authorisation 8 July 2025. GOV.UK
• Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol 1987 — n=14, positive. PMID 3622582
• Monti JM et al. Study of DSIP efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res 1987 — little clinical significance. PMID 3583493
• Bes F et al. Effects of DSIP on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology 1992 — weak effects, n=16. PMID 1299794
• McDermott Will & Emery. PCAC backs majority of peptides in two-day public meeting. 2026 — vote tallies from the July 23–24 PCAC. McDermott
• Baker Hostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 2026 — six peptides covered, including epitalon; DSIP not included. BakerHostetler
• Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab 2006 — hormone data only. PMID 16352683
• Mathias S et al. Systemic GHRH impairs sleep in healthy young women. Psychoneuroendocrinology 2007 — controlled sleep-EEG study. PMID 17850984
• Copinschi G et al. Prolonged oral treatment with MK-677 improves sleep quality in man. Neuroendocrinology 1997 — n=14. PMID 9349662
• Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008 — 2-year RCT; glucose and insulin sensitivity worsened. PMID 18981485
• Yi M et al. Effects of exogenous melatonin on sleep quality and menopausal symptoms: meta-analysis of RCTs. Menopause 2021 — no sleep benefit. PMID 33784263
• Korkushko OV et al. Effect of epithalamin on circadian rhythm of melatonin-producing function in elderly people. Bull Exp Biol Med 2004 — small uncontrolled study. PMID 15452611
• Jain A et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci 2026 — clinically unproven. PMID 42884164